Additionally, MM patients with high SETDB1 expression were more likely to obtain higher β2M (beta-2 microglobulin), LDH (lactate dehydrogenase), BMPC (bone marrow biopsy plasma cells), and lower HGB (haemoglobin), which were all essential biomarkers in MM prognosis (all p < 0.05, Wilcoxon test). The gene discussed is B2M; the disease is Miyoshi myopathy.